en
Conference presentation
English

658MO Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040

Presented atEuropean Society for Medical Oncology (ESMO) Congress, Paris, 9-13 septembre 2022
Publication date2022-09
NotePublié dans : Annals of oncology, 2022, 33, S7, S843
Citation (ISO format)
SOULIERES, D. et al. 658MO Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040. In: European Society for Medical Oncology (ESMO) Congress. Paris. 2022. doi: 10.1016/j.annonc.2022.07.782
Secondary files (1)
Summary
Identifiers
14views
0downloads

Technical informations

Creation12/06/2023 1:55:06 PM
First validation03/20/2024 2:49:13 PM
Update time03/20/2024 2:49:13 PM
Status update03/20/2024 2:49:13 PM
Last indexation03/20/2024 2:49:34 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack